000147733 001__ 147733
000147733 005__ 20240229123029.0
000147733 0247_ $$2doi$$a10.1111/bju.14958
000147733 0247_ $$2pmid$$apmid:31758738
000147733 0247_ $$2ISSN$$a1358-8672
000147733 0247_ $$2ISSN$$a1464-4096
000147733 0247_ $$2ISSN$$a1464-410X
000147733 0247_ $$2altmetric$$aaltmetric:71094235
000147733 037__ $$aDKFZ-2019-02710
000147733 041__ $$aeng
000147733 082__ $$a610
000147733 1001_ $$00000-0001-7505-1740$$aPüllen, Lukas$$b0
000147733 245__ $$aExternal validation of novel MRI-based models for prostate cancer prediction.
000147733 260__ $$aOxford$$bWiley-Blackwell39962$$c2020
000147733 3367_ $$2DRIVER$$aarticle
000147733 3367_ $$2DataCite$$aOutput Types/Journal article
000147733 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1582886811_31851
000147733 3367_ $$2BibTeX$$aARTICLE
000147733 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147733 3367_ $$00$$2EndNote$$aJournal Article
000147733 500__ $$a2020 Mar;125(3):407-416
000147733 520__ $$aTo validate three novel risk models (RM) combining mpMRI and clinical parameters to predict significant prostate cancer (sPC) through an external cohort, including the recently updated European Randomised Study of Screening for PC (ERSPC) risk-calculator.We retrospectively analyzed 307 men who underwent mpMRI prior to transperineal ultrasound fusion biopsy between 10/2015 and 07/2018 at two German centers. mpMRI was rated by PI-RADSv2.0 and sPC was defined as ISUP Gleason grade group ≥2.The prediction performance of the three models (MRI-ERSPC-3/4, RM by Radtke et al. and RM by Distler et al.) were compared using ROC-curve-analyses with area under the curve (AUC), calibration curve analyses and decision curves to assess net-benefit.ROC-AUCs of the three novel models (MRI-ERSPC-3/4; Radtke's RM and Distler's RM were 0.82; 0.85 and 0.83, respectively). Calibration curve analyses showed the best intercept for MRI-ERSPC-3 and -4 of 0.35 and 0.76. Net benefit analyses indicated clear benefit of MRI-ERSPC-3/4-RM compared to the other two validated models. The MRI-ERSPC-RC-3/4 demonstrated a discrimination benefit for a risk threshold of up to 15% for sPC as compared to the other RMs.In our external validation of three novel prostate cancer risk calculators, which include mpMRI-findings in their models, head-to-head comparison of these models indicated that especially MRI-ERSPC-3/4 can help to reduce unnecessary biopsies.
000147733 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000147733 542__ $$2Crossref$$i2019-12-20$$uhttp://doi.wiley.com/10.1002/tdm_license_1.1
000147733 542__ $$2Crossref$$i2019-12-20$$uhttp://onlinelibrary.wiley.com/termsAndConditions#vor
000147733 588__ $$aDataset connected to CrossRef, PubMed,
000147733 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan P$$b1$$udkfz
000147733 7001_ $$0P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aWiesenfarth, Manuel$$b2$$udkfz
000147733 7001_ $$aRoobol, Monique J$$b3
000147733 7001_ $$aVerbeek, Jan F M$$b4
000147733 7001_ $$aWetter, Axel$$b5
000147733 7001_ $$aGuberina, Nika$$b6
000147733 7001_ $$aPandey, Abhishek$$b7
000147733 7001_ $$aHüttenbrink, Clemens$$b8
000147733 7001_ $$aTschirdewahn, Stephan$$b9
000147733 7001_ $$aPahernik, Sascha$$b10
000147733 7001_ $$aHadaschik, Boris A$$b11
000147733 7001_ $$aDistler, Florian A$$b12
000147733 77318 $$2Crossref$$3journal-article$$a10.1111/bju.14958$$bWiley$$d2019-12-20$$n3$$p407-416$$tBJU International$$v125$$x1464-4096$$y2019
000147733 773__ $$0PERI:(DE-600)2019983-1$$a10.1111/bju.14958$$n3$$p407-416$$tBJU international$$v125$$x1464-4096$$y2019
000147733 909CO $$ooai:inrepo02.dkfz.de:147733$$pVDB
000147733 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000147733 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147733 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000147733 9141_ $$y2020
000147733 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147733 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBJU INT : 2015
000147733 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147733 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147733 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147733 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147733 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000147733 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147733 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147733 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147733 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147733 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147733 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147733 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000147733 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000147733 980__ $$ajournal
000147733 980__ $$aVDB
000147733 980__ $$aI:(DE-He78)E010-20160331
000147733 980__ $$aI:(DE-He78)C060-20160331
000147733 980__ $$aUNRESTRICTED
000147733 999C5 $$1Moldovan$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2017.02.026$$p250 -$$tEur Urol$$v72$$y2017
000147733 999C5 $$2Crossref$$uMottet N van den Bergh RCN Briers E et al. European Association of Urology Guidelines 2018
000147733 999C5 $$1Drost$$2Crossref$$oDrost 2019$$y2019
000147733 999C5 $$1Greer$$2Crossref$$9-- missing cx lookup --$$a10.1002/jmri.25372$$p579 -$$tJ Magn Reson Imaging$$v45$$y2017
000147733 999C5 $$1Ahmed$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(16)32401-1$$p815 -$$tLancet$$v389$$y2017
000147733 999C5 $$1Ahmed$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.juro.2011.03.147$$p458 -$$tJ Urol$$v186$$y2011
000147733 999C5 $$1Filson$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.29874$$p884 -$$tCancer$$v122$$y2016
000147733 999C5 $$1Mendhiratta$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.urology.2015.07.038$$p1192 -$$tUrology$$v86$$y2015
000147733 999C5 $$1Panebianco$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.urolonc.2014.09.013$$p17.e1 -$$tUrol Oncol$$v33$$y2015
000147733 999C5 $$1Pokorny$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2014.03.002$$p22 -$$tEur Urol$$v66$$y2014
000147733 999C5 $$1Siddiqui$$2Crossref$$9-- missing cx lookup --$$a10.1001/jama.2014.17942$$p390 -$$tJAMA$$v313$$y2015
000147733 999C5 $$1Valerio$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2014.10.026$$p8 -$$tEur Urol$$v68$$y2015
000147733 999C5 $$1Leest$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2018.11.023$$p570 -$$tEur Urol$$v75$$y2019
000147733 999C5 $$1Rouvière$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(18)30569-2$$p100 -$$tLancet Oncol$$v20$$y2019
000147733 999C5 $$1Kasivisvanathan$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1801993$$p1767 -$$tN Engl J Med$$v378$$y2018
000147733 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/bju.14809$$p9 -$$tBJU Int$$v124$$y2019
000147733 999C5 $$1Gayet$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.euf.2016.07.007$$p228 -$$tEur Urol Focus$$v4$$y2018
000147733 999C5 $$1Louie$$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdu525$$p848 -$$tAnn Oncol$$v26$$y2015
000147733 999C5 $$1Roobol$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00345-011-0804-y$$p149 -$$tWorld J Urol$$v30$$y2012
000147733 999C5 $$1Roobol$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2009.08.025$$p79 -$$tEur. Urol$$v57$$y2010
000147733 999C5 $$1Trottier$$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1464-410X.2011.10207.x$$pE237 -$$tBJU Int.$$v108$$y2011
000147733 999C5 $$1Vugt$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2012.02.002$$p1809 -$$tEur J Cancer$$v48$$y2012
000147733 999C5 $$1Vugt$$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1464-410X.2011.10611.x$$p1480 -$$tBJU Int$$v109$$y2012
000147733 999C5 $$1Vugt$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2010.11.012$$p903 -$$tEur J Cancer$$v47$$y2011
000147733 999C5 $$1Zhu$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2011.11.029$$p652 -$$tEur Urol$$v61$$y2012
000147733 999C5 $$1Distler$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.juro.2017.03.130$$p575 -$$tJ Urol$$v198$$y2017
000147733 999C5 $$1Radtke$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2017.03.039$$p888 -$$tEur Urol$$v72$$y2017
000147733 999C5 $$1Alberts$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2018.07.031$$p310 -$$tEur Urol$$v75$$y2019
000147733 999C5 $$1Radtke$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2015.12.052$$p846 -$$tEur Urol$$v70$$y2016
000147733 999C5 $$1Weinreb$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2015.08.052$$p16 -$$tEur Urol$$v69$$y2016
000147733 999C5 $$1Kuru$$2Crossref$$9-- missing cx lookup --$$a10.1111/bju.12132$$p568 -$$tBJU Int$$v112$$y2013
000147733 999C5 $$1Hadaschik$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.juro.2011.07.102$$p2214 -$$tJ Urol$$v186$$y2011
000147733 999C5 $$1Epstein$$2Crossref$$9-- missing cx lookup --$$a10.1097/01.pas.0000173646.99337.b1$$p1228 -$$tAm J Surg Pathol$$v29$$y2005
000147733 999C5 $$2Crossref$$uSWOP - The Prostate Cancer Research Foundation, Oostvoorne Medical Source data - SWOP - The Prostate Cancer Research Foundation, Oostvoorne http://www.prostatecancer-riskcalculator.com/medical-source-data-2
000147733 999C5 $$1Vickers$$2Crossref$$9-- missing cx lookup --$$a10.1177/0272989X06295361$$p565 -$$tMed Decis Making$$v26$$y2006
000147733 999C5 $$1Kerr$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2015.65.5654$$p2534 -$$tJ Clin Oncol$$v34$$y2016
000147733 999C5 $$1Calster$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2018.08.038$$p796 -$$tEur Urol$$v74$$y2018
000147733 999C5 $$1Moore$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2013.03.030$$p544 -$$tEur Urol$$v64$$y2013
000147733 999C5 $$1Mehralivand$$2Crossref$$9-- missing cx lookup --$$a10.1001/jamaoncol.2017.5667$$p678 -$$tJAMA Oncol$$v4$$y2018
000147733 999C5 $$1Leeuwen$$2Crossref$$9-- missing cx lookup --$$a10.1111/bju.13814$$p774 -$$tBJU Int$$v120$$y2017
000147733 999C5 $$1Woo$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.eururo.2017.01.042$$p177 -$$tEur Urol$$v72$$y2017